Literature DB >> 7829637

CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population.

T Yanagawa1, Y Hidaka, V Guimaraes, M Soliman, L J DeGroot.   

Abstract

Graves' disease (GD) is an autoimmune thyroid disease. Multiple genetic factors are believed to be involved in its pathogenesis, but the factors are largely unknown, except for sex (female disease preponderance) and the role of human leukocyte antigen (HLA) genes on chromosome 6. To understand the mechanisms underlying the development of GD, a search for non-HLA-linked genes is crucial, and we tested several candidate genes, including the CTLA-4 gene on chromosome 2q33. CTLA-4 molecules may either facilitate or down-regulate the second signal to T-cells, which is provided by the interaction between the two accessory molecules CD28 and B7. One hundred and thirty-three Caucasian patients (26 males) with GD and 85 local controls were included in this study. Polymerase chain reaction was used to amplify DNA containing the (AT)n repeat within the 3'-untranslated region of exon 3 of the CTLA-4 gene. The 5'-forward primer was radiolabeled, and amplified products were resolved on 5-7% sequencing gels. All subjects were previously typed for HLA class II alleles. Twenty-one alleles were observed with sizes ranging from 88-134 basepairs. In the association analysis, the genotype frequencies between GD patients and controls differed significantly (P = 0.012), and the difference was attributable to a higher frequency of the 106-basepair allele among patients (relative risk, 2.82). When the patients were subdivided with respect to sex and HLA, the phenotype frequencies of allele 106 was higher in the female patients with protective HLA specificities (DQA1*0201 positive/DQA1*0501 negative) than in those with susceptible HLA specificities (DQA1*0201 negative/DQA1*0501 positive; 81.8% vs. 45.5%; P = 0.026). The CTLA-4 gene or a closely associated gene (including CD28) confers susceptibility to GD. This association may be more important in female patients with protective HLA specificities, who otherwise would be at low risk of developing the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7829637     DOI: 10.1210/jcem.80.1.7829637

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  77 in total

1.  Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy.

Authors:  Xiaoming Yin; Rauf Latif; Rebecca Bahn; Terry F Davies
Journal:  Thyroid       Date:  2012-06-04       Impact factor: 6.568

2.  Association study of autoimmune thyroid disease at 5q23-q33 in Japanese patients.

Authors:  Takashi Akamizu; Hitomi Hiratani; Satoshi Ikegami; Stephen S Rich; Donald W Bowden
Journal:  J Hum Genet       Date:  2003-04-09       Impact factor: 3.172

Review 3.  CTLA4 gene and autoimmune endocrinopathies: a new marker?

Authors:  F Pociot
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 4.  Genetic susceptibility in type 1 diabetes and its associated autoimmune disorders.

Authors:  Akane Ide; George S Eisenbarth
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

5.  Genetics of thyroid function and disease.

Authors:  Vijay Panicker
Journal:  Clin Biochem Rev       Date:  2011-11

6.  Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors:  Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal:  Oncologist       Date:  2019-10-10

7.  Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families.

Authors:  Yaron Tomer; Yoshiyuki Ban; Erlinda Concepcion; Giuseppe Barbesino; Ronald Villanueva; David A Greenberg; Terry F Davies
Journal:  Am J Hum Genet       Date:  2003-09-12       Impact factor: 11.025

Review 8.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

Review 9.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 10.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.